JPWO2020184479A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020184479A5 JPWO2020184479A5 JP2021505049A JP2021505049A JPWO2020184479A5 JP WO2020184479 A5 JPWO2020184479 A5 JP WO2020184479A5 JP 2021505049 A JP2021505049 A JP 2021505049A JP 2021505049 A JP2021505049 A JP 2021505049A JP WO2020184479 A5 JPWO2020184479 A5 JP WO2020184479A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- weight
- ophthalmic composition
- trpa1
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 11
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 10
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 10
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 7
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 7
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims 6
- 230000007794 irritation Effects 0.000 claims 6
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 claims 5
- YGWKXXYGDYYFJU-SSDOTTSWSA-N (+)-menthofuran Chemical compound C1[C@H](C)CCC2=C1OC=C2C YGWKXXYGDYYFJU-SSDOTTSWSA-N 0.000 claims 5
- 239000001745 (6R)-3,6-dimethyl-4,5,6,7-tetrahydro-1-benzofuran Substances 0.000 claims 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims 5
- 241000723346 Cinnamomum camphora Species 0.000 claims 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 5
- NOOLISFMXDJSKH-LPEHRKFASA-N Isomenthol Natural products CC(C)[C@@H]1CC[C@H](C)C[C@H]1O NOOLISFMXDJSKH-LPEHRKFASA-N 0.000 claims 5
- YGWKXXYGDYYFJU-UHFFFAOYSA-N Menthofuran Natural products C1C(C)CCC2=C1OC=C2C YGWKXXYGDYYFJU-UHFFFAOYSA-N 0.000 claims 5
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 claims 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 5
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 5
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 5
- 230000001387 anti-histamine Effects 0.000 claims 5
- 239000000739 antihistaminic agent Substances 0.000 claims 5
- 229930008380 camphor Natural products 0.000 claims 5
- 229960000846 camphor Drugs 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229930007050 cineol Natural products 0.000 claims 5
- 229960005233 cineole Drugs 0.000 claims 5
- 239000000850 decongestant Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229940087305 limonene Drugs 0.000 claims 5
- 235000001510 limonene Nutrition 0.000 claims 5
- 239000003589 local anesthetic agent Substances 0.000 claims 5
- 229930007503 menthone Natural products 0.000 claims 5
- -1 pinene Chemical compound 0.000 claims 5
- 229940123223 TRPA1 agonist Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024177773A JP2024180505A (ja) | 2019-03-08 | 2024-10-10 | 刺激感が抑制された眼科組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019043089 | 2019-03-08 | ||
| JP2019071396 | 2019-04-03 | ||
| PCT/JP2020/009847 WO2020184479A1 (ja) | 2019-03-08 | 2020-03-06 | 刺激感が抑制された眼科組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177773A Division JP2024180505A (ja) | 2019-03-08 | 2024-10-10 | 刺激感が抑制された眼科組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2020184479A1 JPWO2020184479A1 (enExample) | 2020-09-17 |
| JPWO2020184479A5 true JPWO2020184479A5 (enExample) | 2023-03-10 |
Family
ID=72427534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505049A Pending JPWO2020184479A1 (enExample) | 2019-03-08 | 2020-03-06 | |
| JP2024177773A Pending JP2024180505A (ja) | 2019-03-08 | 2024-10-10 | 刺激感が抑制された眼科組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177773A Pending JP2024180505A (ja) | 2019-03-08 | 2024-10-10 | 刺激感が抑制された眼科組成物 |
Country Status (4)
| Country | Link |
|---|---|
| JP (2) | JPWO2020184479A1 (enExample) |
| CN (1) | CN113423428A (enExample) |
| TW (1) | TW202100144A (enExample) |
| WO (1) | WO2020184479A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230350228A1 (en) | 2022-04-28 | 2023-11-02 | Coopervision International Limited | Contact lens |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4505909A (en) * | 1980-09-17 | 1985-03-19 | Bernstein Joel E | Method and composition for treating and preventing irritation of the eyes |
| JP3597239B2 (ja) * | 1994-03-31 | 2004-12-02 | ライオン株式会社 | 安定な点眼剤 |
| JPH09132526A (ja) * | 1995-11-09 | 1997-05-20 | Lion Corp | 点眼剤 |
| JPH09169642A (ja) * | 1995-12-18 | 1997-06-30 | Lion Corp | テトラヒドロゾリン含有液剤 |
| JPH09309835A (ja) * | 1996-05-21 | 1997-12-02 | Lion Corp | グリチルリチン酸アルキルエステル含有薬液 |
| JP2000327573A (ja) * | 1999-05-18 | 2000-11-28 | Taisho Pharmaceut Co Ltd | 粘膜適用組成物 |
| JP2001302518A (ja) * | 2000-02-15 | 2001-10-31 | Rohto Pharmaceut Co Ltd | 官能改善方法および官能改善剤 |
| JP2003073303A (ja) * | 2001-09-05 | 2003-03-12 | Senju Pharmaceut Co Ltd | 眼局所用液剤の清涼化作用の持続方法 |
| JP4174648B2 (ja) * | 2001-11-12 | 2008-11-05 | ロート製薬株式会社 | 水性組成物 |
| JP2003183157A (ja) * | 2001-12-19 | 2003-07-03 | Lion Corp | 眼科用組成物 |
| US6982079B2 (en) * | 2002-04-26 | 2006-01-03 | Allergan, Inc. | Compositions for treating hyperemia |
| JP2004143156A (ja) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | 点眼剤 |
| JP2004175770A (ja) * | 2002-11-29 | 2004-06-24 | Rohto Pharmaceut Co Ltd | ケトチフェン及びイミダゾリン化合物含有組成物 |
| JP5695913B2 (ja) * | 2003-04-04 | 2015-04-08 | ロート製薬株式会社 | 眼科用組成物 |
| JP5661981B2 (ja) * | 2004-11-26 | 2015-01-28 | 大正製薬株式会社 | 眼科用剤 |
| JP4979258B2 (ja) * | 2005-04-08 | 2012-07-18 | ロート製薬株式会社 | アシタザノラスト含有水性組成物 |
| JP5052028B2 (ja) * | 2005-04-08 | 2012-10-17 | ロート製薬株式会社 | アシタザノラスト含有組成物 |
| WO2007108541A1 (ja) * | 2006-03-23 | 2007-09-27 | Senju Pharmaceutical Co., Ltd. | キサンタンガムおよびブドウ糖を含有する眼科用組成物 |
| JP2008024700A (ja) * | 2006-06-23 | 2008-02-07 | Rohto Pharmaceut Co Ltd | ベルベリン含有水性組成物 |
| JP5258329B2 (ja) * | 2007-06-01 | 2013-08-07 | ロート製薬株式会社 | プラノプロフェン含有水性医薬組成物 |
| JP2009029779A (ja) * | 2007-06-29 | 2009-02-12 | Rohto Pharmaceut Co Ltd | レボカバスチン及び／又はその塩を含有する水性医薬組成物 |
| JP5595206B2 (ja) * | 2009-09-30 | 2014-09-24 | ロート製薬株式会社 | 眼科用液体組成物 |
| WO2011040572A1 (ja) * | 2009-09-30 | 2011-04-07 | ロート製薬株式会社 | 眼科組成物 |
| JP2012144509A (ja) * | 2011-01-12 | 2012-08-02 | Saga Seiyaku Kk | 多成分配合の点眼剤 |
| JP5736211B2 (ja) * | 2011-03-29 | 2015-06-17 | ロート製薬株式会社 | 眼科用組成物 |
| JP6180115B2 (ja) * | 2012-01-05 | 2017-08-16 | 花王株式会社 | 刺激感緩和剤 |
| EP2620137B1 (de) * | 2012-01-30 | 2017-11-15 | Symrise AG | Zubereitungen |
| JP2013237638A (ja) * | 2012-05-15 | 2013-11-28 | Lion Corp | 眼科組成物 |
| US20130315843A1 (en) * | 2012-05-25 | 2013-11-28 | The Procter & Gamble Company | Composition for reduction of trpa1 and trpv1 sensations |
| JP6177594B2 (ja) * | 2012-06-14 | 2017-08-09 | ロート製薬株式会社 | 水性眼科組成物 |
| JP6353365B2 (ja) * | 2012-09-27 | 2018-07-04 | 千寿製薬株式会社 | 水性液剤 |
| JP6177019B2 (ja) * | 2013-01-31 | 2017-08-09 | ロート製薬株式会社 | 点眼剤 |
| JP5730355B2 (ja) * | 2013-07-24 | 2015-06-10 | 学校法人近畿大学 | Ｃｙｐ２ａ１３阻害剤 |
| EP3093002B1 (de) * | 2015-05-15 | 2018-04-25 | Symrise AG | Flüssige kühlstoffzubereitungen |
| JP2017119669A (ja) * | 2015-10-15 | 2017-07-06 | ロート製薬株式会社 | 異物感改善用眼科組成物 |
| EP3481808A4 (en) * | 2016-07-06 | 2020-07-15 | Algomedix, Inc. | TRPA1 ANTAGONISTS FOR THE TREATMENT OF DRY EYE SYNDROME, EYE PAIN AND INFLAMMATION |
-
2020
- 2020-03-06 JP JP2021505049A patent/JPWO2020184479A1/ja active Pending
- 2020-03-06 WO PCT/JP2020/009847 patent/WO2020184479A1/ja not_active Ceased
- 2020-03-06 TW TW109107480A patent/TW202100144A/zh unknown
- 2020-03-06 CN CN202080013192.3A patent/CN113423428A/zh active Pending
-
2024
- 2024-10-10 JP JP2024177773A patent/JP2024180505A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7273731B2 (ja) | シロシビン誘導体を含む組成物及び方法 | |
| DaVanzo et al. | Pharmacological and biochemical studies in isolation-induced fighting mice | |
| Dybdal-Hargreaves et al. | Mephedrone: Public health risk, mechanisms of action, and behavioral effects | |
| CN111655241B (zh) | 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法 | |
| JP5616620B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JP5688953B2 (ja) | イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| WO2004069157A2 (en) | Combinational use of long-acting and short-acting anti-histamines for ocular allergies | |
| JP5616618B2 (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JP2020128437A (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JPWO2020184479A5 (enExample) | ||
| HUE027076T2 (en) | Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases | |
| JP6653123B2 (ja) | カラーコンタクトレンズ用眼科組成物 | |
| Avalos et al. | Effects of pyridine ring substitutions on affinity, efficacy, and subtype selectivity of neuronal nicotinic receptor agonist epibatidine | |
| JP5725786B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| EP3720411A1 (en) | Topical ointment formulations of pde-4 inhibitor and their use in treating skin conditions | |
| CA3144983A1 (en) | Treatment of pain using allosteric modulator of trpv1 | |
| JP5506357B2 (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JP5616616B2 (ja) | シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
| Huang et al. | Role of endothelium in thapsigargin-induced arterial responses in rat aorta | |
| JP2020109125A (ja) | 眼科組成物 | |
| JP7320638B2 (ja) | 眼科組成物による眼への刺激を緩和する方法、眼科組成物中のメントールの芳香性を持続させる方法、及び、眼科組成物によるソフトコンタクトレンズの変質を抑制する方法 | |
| RU2840921C2 (ru) | Изоксазолиновые паразитицидные составы и способы лечения блефарита | |
| NO20060456L (no) | Ren D-(17a)-13-etyl-17-hydroksy-18,19-dinorpregn-4-en-20-yn-3-on-3E og 3Z-oksimisomerer, samt fremgangsmater for syntesene av blandingen av isomerer og de rene isomerene | |
| WO2013068876A1 (en) | Methods and compositions for treating ocular allergy | |
| HK40036019A (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis |